Analysis of new oral immunotherapy with Cry j1-galactomannan conjugate for Japanese cedar pollinosis

在这项研究中，我们首次评估了一种新的短期口服免疫疗法(OIT)的安全性和有效性，该疗法使用Cry J1-半乳甘露聚糖结合物治疗日本雪松花粉症，该结合物可能包括高剂量过敏原，并可以降低过敏反应的风险。从花粉季前一个月开始接受OIT约两个月的参与者显示，与对照组相比，在整个花粉季以及下一个没有OIT的花粉季，鼻结膜炎和药物使用都有显着改善。重要的是，在接受OIT的参与者中没有观察到威胁生命的副作用。这些结果表明，使用过敏原-半乳甘露聚糖结合物的新的短期OIT可能为日本雪松花粉症提供一种快速、方便、有效和安全的免疫治疗方案。

In this study, we assessed for the first time the safety and efficacy of a new short-term oral immunotherapy (OIT) for Japanese cedar pollinosis using the Cry j1-galactomannan conjugates, which could include high-dose allergens and could be decreased the risk of anaphylaxis. Participants receiving OIT for about two months from a month before the pollen season showed significant improvements in rhinoconjunctivitis and medication use through the pollen season and furthermore the next pollen season without OIT compared with control group. Importantly, no side effects such as life-threatening were observed in participants receiving OIT.These results suggest that a new short-term OIT using allergen-galactomannan conjugates may provide a rapid, convenient, effective, and safe immunotherapy regimen for Japanese cedar pollinosis.